Meeting
2019 Genitourinary Cancers Symposium
ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA
Mary-Ellen Taplin , Arif Hussain , Satish Shah , Neal D. Shore , Manish Agrawal , William Clark , William Jeffery Edenfield , Luke T. Nordquist , Oliver A Sartor , James E. Butrynski , Gurkamal S. Chatta , Mark T. Fleming , William K. Oh , Bill Bradley , Jessica Piel , David Nash , Gozde Colak , Jian Li , Claudia Lebedinsky , Emmanuel S. Antonarakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03480646
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS335)
DOI
10.1200/JCO.2019.37.7_suppl.TPS335
Abstract #
TPS335
Poster Bd #
N11
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Wassim Abida
Poster
2018 Genitourinary Cancers Symposium
A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC).
First Author: Mary-Ellen Taplin
Poster
2023 ASCO Genitourinary Cancers Symposium
A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Mariona Calvo
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal